HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN

WIPO Patent Application WO/2024/034593

A1

Provided is a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and/or lung cancer.　The present inventors examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and/or lung cancer and found that a heterocyclic compound represented by formula (I) has an excellent action for inducing the degradation of G12V mutant KRAS protein and an inhibitory activity on G12V mutant KRAS and can be used as a therapeutic agent for pancreatic cancer and/or lung cancer. The present invention has been completed on the basis of this finding. The heterocyclic compound of the present invention or a salt thereof can be used as a therapeutic agent for pancreatic cancer and/or lung cancer.

MORIKAWA TAKAHIRO (JP)
IMAIZUMI TOMOYOSHI (JP)
OKUMURA MITSUAKI (JP)
HAMAGUCHI HISAO (JP)
IMADA SUNAO (JP)
KOGANEMARU YOHEI (JP)
KAWAMINAMI EIJI (JP)
YOSHINARI TOMOHIRO (JP)
KURAMOTO KAZUYUKI (JP)
NISHIZONO YOSHIHIRO (JP)

PCT/JP2023/028864

February 15, 2024

August 08, 2023

Click for automatic bibliography generation  

ASTELLAS PHARMA INC (JP)

C07D401/14; A61K31/496; A61K31/513; A61K31/517; A61P35/00; A61P43/00; C07D403/14; C07D405/14; C07D471/10; C07D487/10

WO2017172979A1	2017-10-05
WO2018143315A1	2018-08-09
WO2021185291A1	2021-09-23
WO2021051034A1	2021-03-18
WO2022111521A1	2022-06-02
WO2022061348A1	2022-03-24
WO2022173032A1	2022-08-18

US20180015087A1	2018-01-18
JP2021521112A	2021-08-26

YAMAMOTO, Osamu et al. (JP)

View/Download PDF      PDF Help

Previous Patent: AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING UDCA OR SALT THEREOF

Next Patent: METHOD FOR REMOVING POLLUTANTS